High 15-f-2t-isoprostane Levels In Patients With A Previous History Of Nonmelanoma Skin Cancer: The Effects Of Supplementary Antioxidant Therapy

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Background. Phase I of this study was aimed at comparing the profiles of oxidative stress biomarkers in patients with history of nonmelanoma skin cancer (NMSC), previously treated with surgery, to the healthy subjects. Phase II aimed to evaluate the effects of supplementary antioxidant therapy on the levels of biomarkers in the case group. Materials and Methods. In Phase I, oxidative stress biomarkers were measured in blood samples obtained from 24 healthy subjects and 60 patients with history of NMSC previously treated with surgery. In Phase II, the 60 patients with history of NMSC were randomized into two subgroups, one receiving placebo (n = 34) and the other (n = 26) receiving vitamin C, vitamin E, and zinc supplementation for 8 weeks, followed by reevaluation of biomarkers. Results. In Phase I, patients with history of NMSC showed increased plasma concentrations of all biomarkers, but only 15-F-2t-isoprostane was significantly higher than in the healthy subjects. Risk of NMSC increased by 4% for each additional 1 pg/mL increase in 15-F-2t-isoprostane. In Phase II, supplementation did not significantly reduce levels of oxidative stress biomarkers. Conclusion. Patients with history of NMSC had significantly high 15-F-2t-isoprostane plasma levels; supplementation did not result in significant reduction of oxidative stress biomarkers. This trial was registered with ClinicalTrials.gov (ID NCT02248584).Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)CNPq [482958/2011-1

High 15-f-2t-isoprostane levels in patients with a previous history of nonmelanoma skin cancer: the effects of supplementary antioxidant therapy

Phase I of this study was aimed at comparing the profiles of oxidative stress biomarkers in patients with history of nonmelanoma skin cancer (NMSC), previously treated with surgery, to the healthy subjects. Phase II aimed to evaluate the effects of supplementary antioxidant therapy on the levels of biomarkers in the case group. In Phase I, oxidative stress biomarkers were measured in blood samples obtained from 24 healthy subjects and 60 patients with history of NMSC previously treated with surgery. In Phase II, the 60 patients with history of NMSC were randomized into two subgroups, one receiving placebo (n = 34) and the other (n = 26) receiving vitamin C, vitamin E, and zinc supplementation for 8 weeks, followed by reevaluation of biomarkers. Results. In Phase I, patients with history of NMSC showed increased plasma concentrations of all biomarkers, but only 15-F-2t-isoprostane was significantly higher than in the healthy subjects. Risk of NMSC increased by 4% for each additional 1 pg/mL increase in 15-F-2t-isoprostane. In Phase II, supplementation did not significantly reduce levels of oxidative stress biomarkers. Patients with history of NMSC had significantly high 15-F-2t-isoprostane plasma levels; supplementation did not result in significant reduction of oxidative stress biomarkers. This trial was registered with ClinicalTrials.gov (ID NCT02248584)2015CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICO - CNPQFUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESP482958/2011-1sem informaçã

High 15-f2t-isoprostane Levels In Patients With A Previous History Of Nonmelanoma Skin Cancer: The Effects Of Supplementary Antioxidant Therapy.

Phase I of this study was aimed at comparing the profiles of oxidative stress biomarkers in patients with history of nonmelanoma skin cancer (NMSC), previously treated with surgery, to the healthy subjects. Phase II aimed to evaluate the effects of supplementary antioxidant therapy on the levels of biomarkers in the case group. In Phase I, oxidative stress biomarkers were measured in blood samples obtained from 24 healthy subjects and 60 patients with history of NMSC previously treated with surgery. In Phase II, the 60 patients with history of NMSC were randomized into two subgroups, one receiving placebo (n = 34) and the other (n = 26) receiving vitamin C, vitamin E, and zinc supplementation for 8 weeks, followed by reevaluation of biomarkers. In Phase I, patients with history of NMSC showed increased plasma concentrations of all biomarkers, but only 15-F2t-isoprostane was significantly higher than in the healthy subjects. Risk of NMSC increased by 4% for each additional 1 pg/mL increase in 15-F2t-isoprostane. In Phase II, supplementation did not significantly reduce levels of oxidative stress biomarkers. Patients with history of NMSC had significantly high 15-F2t-isoprostane plasma levels; supplementation did not result in significant reduction of oxidative stress biomarkers. This trial was registered with ClinicalTrials.gov (ID NCT02248584).201596356

Relationship between oxidative stress, excretion of cisplatin and nephrotoxicity in patients with head and neck cancer treated with high-dose cisplatin and radiotherapy

Orientador: Patricia MorielDissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciências MédicasResumo: A cisplatina (CDDP) é um agente antitumoral potente e citotóxico, indicado para o tratamento de carcinoma de células escamosas de cabeça e pescoço (CCECP), concomitante a radioterapia. Seu uso está limitado devido ao surgimento de intensos efeitos adversos, como exemplo a nefrotoxicidade. O objetivo deste trabalho foi avaliar o estresse oxidativo antes e após a quimioterapia com CDDP (fase 1), e correlacioná-lo com a excreção de CDDP na urina (fase 2), avaliando a nefrotoxicidade. Foi realizado um estudo clínico observacional, longitudinal prospectivo, quantitativo, com amostragem consecutiva, realizado de agosto de 2011 a dezembro de 2013 no Hospital de Clínicas/UNICAMP. Foram incluídos sujeitos de ambos os sexos, entre 18 e 80 anos, com diagnóstico de CCECP, em seu primeiro dia (caso novo) no Ambulatório de Oncologia Clínica, que receberam como conduta terapêutica 3 ciclos de quimioterapia com altas doses de CDDP e radioterapia concomitante. Os sujeitos foram acompanhados pela equipe de farmácia clínica no dia do caso novo, em todos os retornos com a equipe médica (pré quimioterapia, após os 3 ciclos de quimioterapia), como também nos dias das quimioterapias. Foram investigados biomarcadores de estresse oxidativo (através dos testes de TBARS, FOX-2 e Nitrito) e excreção de CDDP (0-12, 12-24 e 24-48 horas após a quimioterapia), ambos na urina, como também a nefrotoxicidade (variação de creatinina, Cr e clearance de creatinina, ClCr). Para todas as análises considerou-se significativo p < 0,05. Na fase 1 (n = 33) os sujeitos apresentaram idade média de 55 anos, sendo a maioria homens, brancos, tabagistas e etilistas acentuados, com tumores localizados na faringe, e com pico de estresse oxidativo no período 0-12h após a administração de CDDP. A excreção de CDDP também apresentou maiores valores no período 0-12h, evidenciando uma relação entre eles. Pode-se observar que houve relação entre o período basal e 0-12h dos testes de FOX-2 e nitrito, demonstrando que após a administração de CDDP existe aumento do estresse oxidativo, porém este não se relaciona com os parâmetros de nefrotoxicidade. Na fase 2 (n= 95) os sujeitos apresentaram características semelhantes à fase 1, e não houve relação significativa entre estresse oxidativo, excreção de CDDP e parâmetros de nefrotoxicidade. Portanto este estudo sugere que existe o aumento de estresse nitrosativo e oxidativo após a administração de CDDP em pacientes com câncer de cabeça e pescoçoAbstract: Cisplatin (CDDP) is a potent cytotoxic and anticancer agent, indicated for the treatment of head and neck squamous cell carcinoma (HNSCC), concomitant radiotherapy. Its use is limited owing of severe side effects, mainly nephrotoxicity. The aim of this study was to evaluate oxidative stress before and after chemotherapy with CDDP (phase 1), and correlate it with urinary excretion (phase 2), and nephrotoxicity of CDDP. An observational clinical study, prospective longitudinal, and quantitative, with consecutive sampling during August 2011 to December 2013 at the Hospital de Clínicas/UNICAMP was performed. We included patients of both sexes, between 18 and 80 years, diagnosed with HNSCC, on his first day (new case) at the Clinical Oncology, who received a therapeutic conduct of 3 cycles of chemotherapy with high-dose cisplatin concomitant radiotherapy. The patients were followed up by clinical pharmacy staff in the new case and all returns with the medical team (pre chemotherapy, after 3 cycles of chemotherapy), and in the days of chemotherapy. Biomarkers of oxidative stress (using the TBARS test, FOX-2 and nitrite in urine) and excretion of CDDP (0-12, 12-24 and 24-48 hours after chemotherapy), both in urine, were investigated, as well as nephrotoxicity (creatinine variation, Cr and creatinine clearance, CrCl). A p value less than 0.05 were considered significant. In phase 1 (n = 33) patients had a mean age of 55 years, mostly white men, smokers and alcoholics accented with tumors located in the pharynx, and with a increased in oxidative stress in 0-12h after administration of CDDP. The excretion of CDDP also showed higher values during 0-12h, showing a relationship between them. It can be seen that there was a relationship between the baseline and the 0-12h of FOX-2 and nitrite test, indicating that after administration of CDDP there is increase in oxidative stress, but this is not related to the parameters of nephrotoxicity. In phase 2 (n = 95) patients showed characteristics similar to phase 1, and there was no significant relationship between oxidative stress parameters, excretion of CDDP, and nephrotoxicity. Therefore, this study suggests that there is an increase of nitrosative and oxidative stress after administration of cisplatin in patients with head and neck cancerMestradoCiencias BiomedicasMestra em Ciências Médica

Antioxidant Capacity Total In Non-melanoma Skin Cancer And Its Relationship With Food Consumption Of Antioxidant Nutrients

The non-melanoma skin cancer is the most common cancer and accounts for more than half of the diagnoses of cancer, and basal cell carcinoma (BCC), the most frequent cutaneous neoplasm, corresponding to 70-80% of cutaneous tumors. Oxidative stress is an important trigger for skin carcinogenesis. Thus, it is important to evaluate oxidative stress, in order to discern effective therapeutic strategies able to stop it or attenuate it, thereby prevent the installation of non-melanoma skin cancer. Cross-sectional study with controls, involving 84 individuals of both sexes aged between 38-84 years, divided into two groups: control group of healthy people(n = 24) and the case group included individuals who presented non-melanoma skin and they have undergoing surgery (n = 60). The blood samples of the individuals were obtained for evaluation of biomarkers of oxidative stress (F2-isoprostane, nitrite, thiobarbituric acid reactive substances (TBARS) and total antioxidant capacity). The usual dietary intake and nutritional status of the subjects were evaluated. The significance level for this study was 5%. Patients in the case group had higher serum concentrations of biomarkers of oxidative stress, F2-isoprostane concentrations were significantly higher compared to controls. The results showed high rates of overweight and obesity in the case and control groups. The dietary concentrations of antioxidant minerals zinc, copper and selenium in the case group were significantly lower compared to controls. The correlation between markers of oxidative stress and dietary concentrations of antioxidant nutrients showed the influence of food intake of vitamins A and E in reducing oxidative stress, since these nutrients behave as important antioxidants, acting as sweepers of RL, by removing of the body the negative effects on the redox balance of the skin. We emphasize the importance of adopting healthy eating habits that optimize the consumption of antioxidant nutrients as a strategy to prevent oxidative damage to the skin.3141682168

Influence of sex in alcohol‐related liver disease: Pre‐clinical and clinical settings

Alcohol-related liver disease (ArLD) is a major cause of chronic liver disease globally. Traditionally, ArLD was mostly a concern in men rather than in women; however, such a sex gap is rapidly narrowing due to increasing chronic alcohol consumption among women. Female sex is more vulnerable to the harmful effects of alcohol with a higher risk of progression to cirrhosis and development of associated complications. The relative risk of cirrhosis and liver-related mortality is significantly higher in women than in men. Our review endeavors to summarize the current knowledge on sex differences in alcohol metabolism, pathogenesis of ArLD, disease progression, indication for liver transplant and pharmacological treatments of ArLD, and provide evidence in support of a sex-specific management of these patients

Nausea, Vomiting And Quality Of Life Of Patients With Cancer Undergoing Antineoplastic Treatment: An Evaluation By Pharmacists.

This study aims to evaluate the frequency and severity of nausea and vomiting using two different instruments and relate them to quality of life (QOL) in patients with cancer receiving antineoplastic treatment. Severity of chemotherapy-induced nausea and vomiting (CINV) was measured by Common Terminology Criteria for Adverse Events (CTCAE) and a numerical scale. QOL was assessed using the Functional Assessment of Cancer Therapy-General questionnaire. Of the 50 patients studied, 60.0% reported nausea (40.0% CTCAE grade 1; 66.7% moderate intensity on numerical scale) and 30.0% reported vomiting (46.7% CTCAE grades 1 and 2, each; 66.7% moderate intensity on numerical scale). CINV did not influence overall QOL. The frequency of CINV was high. There was no association between nausea/vomiting and overall QOL

Clinical Study High 15-F 2t -Isoprostane Levels in Patients with a Previous History of Nonmelanoma Skin Cancer: The Effects of Supplementary Antioxidant Therapy

Background. Phase I of this study was aimed at comparing the profiles of oxidative stress biomarkers in patients with history of nonmelanoma skin cancer (NMSC), previously treated with surgery, to the healthy subjects. Phase II aimed to evaluate the effects of supplementary antioxidant therapy on the levels of biomarkers in the case group. Materials and Methods. In Phase I, oxidative stress biomarkers were measured in blood samples obtained from 24 healthy subjects and 60 patients with history of NMSC previously treated with surgery. In Phase II, the 60 patients with history of NMSC were randomized into two subgroups, one receiving placebo ( = 34) and the other ( = 26) receiving vitamin C, vitamin E, and zinc supplementation for 8 weeks, followed by reevaluation of biomarkers. Results. In Phase I, patients with history of NMSC showed increased plasma concentrations of all biomarkers, but only 15-F 2t -isoprostane was significantly higher than in the healthy subjects. Risk of NMSC increased by 4% for each additional 1 pg/mL increase in 15-F 2t -isoprostane. In Phase II, supplementation did not significantly reduce levels of oxidative stress biomarkers. Conclusion. Patients with history of NMSC had significantly high 15-F 2t -isoprostane plasma levels; supplementation did not result in significant reduction of oxidative stress biomarkers. This trial was registered with ClinicalTrials.gov (ID NCT02248584)